key: cord-0923129-zmqa68hn
authors: Wang, Yuhang; Grunewald, Matthew; Perlman, Stanley
title: Coronaviruses: An Updated Overview of Their Replication and Pathogenesis
date: 2020-08-25
journal: Coronaviruses
DOI: 10.1007/978-1-0716-0900-2_1
sha: 3eb28994b4c8a76d1153aae6d3f810ecd2341339
doc_id: 923129
cord_uid: zmqa68hn

Coronaviruses (CoVs), enveloped positive-sense RNA viruses, are characterized by club-like spikes that project from their surface, an unusually large RNA genome, and a unique replication strategy. CoVs cause a variety of diseases in mammals and birds ranging from enteritis in cows and pigs, and upper respiratory tract and kidney disease in chickens to lethal human respiratory infections. Most recently, the novel coronavirus, SARS-CoV-2, which was first identified in Wuhan, China in December 2019, is the cause of a catastrophic pandemic, COVID-19, with more than 8 million infections diagnosed worldwide by mid-June 2020. Here we provide a brief introduction to CoVs discussing their replication, pathogenicity, and current prevention and treatment strategies. We will also discuss the outbreaks of the highly pathogenic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), which are relevant for understanding COVID-19.

CoVs, the largest group of viruses within the Nidovirales order, comprises Coronaviridae, Arteriviridae, Roniviridae, and Mesoniviridae families. The Coronavirinae include one of two subfamilies in the Coronaviridae family, with the other subfamily being Torovirinae. The Coronavirinae are further subdivided into four genera: the α, β, γ, and δ-CoVs. The viruses were initially sorted into these groups based on serology but now are divided by phylogenetic clustering and pairwise evolutionary distances in seven key domains of the replicase-transcriptase polyprotein. The arteriviruses consist of five genera of mammalian pathogens. The roniviruses, which infect shrimp and the mosquito-borne mesoniviruses have invertebrate hosts.

All viruses in the Nidovirales order are enveloped, nonsegmented positive-sense RNA viruses. They share a significant number of common features including (a) a highly conserved genomic organization, with a large replicase gene upstream of structural and accessory genes; (b) expression of many nonstructural protein genes by ribosomal frameshifting; (c) several unique or unusual enzymatic activities encoded within the large replicase-transcriptase protein product; and (d) expression of downstream genes by synthesis of 3 0 nested subgenomic mRNAs. In fact, the Nidovirales order name is derived from these nested 3 0 mRNAs as nido is Latin for "nest." The major differences within the four Nidovirus families are in the numbers, types, and sizes of their structural proteins and significant alterations in the structure and morphology of their virions and nucleocapsids.

Nidoviruses, which include CoVs, have the largest identified RNA genomes; CoVs contain approximately 30 kilobases (kb). The genome contains a 5 0 cap structure along with a 3 0 poly(A) tail, allowing it to act as a mRNA for translation of the replicase polyproteins. The replicase gene encoding the nonstructural proteins (nsps) occupies two-thirds of the genome, about 20 kb, as opposed to the structural and accessory proteins, which make up about 10 kb of the viral genome. The 5 0 end of the genome contains a leader sequence and untranslated region (UTR) that contains multiple stem loop structures required for RNA replication and transcription. Additionally, at the beginning of each structural or accessory gene are transcriptional regulatory sequences (TRSs) that are required for expression of each of these genes. The 3 0 -UTR also contains RNA structures required for replication and synthesis of viral RNA. The organization of the CoVs genome is 5 0 -leader-UTR-replicase-S (Spike)-E (Envelope)-M (Membrane)-N (Nucleocapsid)-3 0 -UTR-poly(A) tail with accessory genes interspersed within the structural genes at the 3 0 end of the genome (see Fig. 1 ). As shown using reverse genetics with deletion of these accessory genes, accessory proteins are almost exclusively nonessential for replication in tissue culture; however, some have been shown to have profound roles in viral pathogenesis [1] [2] [3] [4] [5] . In some cases, accessory proteins inhibit the host defense response, especially innate immune mechanisms. For example, during MERS-CoV infection, accessory ORFs 3-5 antagonize the innate immune response [6] ; ORF4a binds to dsRNA, inhibiting type I interferon (IFN-I) expression and prevents the antiviral stress response [7, 8] ; ORF4b inhibits IFN-I expression [9] and blocks NF-kB signaling [10] . ORF4b also encodes a cyclic phosphodiesterase, which blocks RNaseL activation [11] .

CoVs virions are spherical with diameters of approximately 125 n as depicted in studies by cryo-electron tomography and cryo-electron microscopy [12, 13] . The most prominent feature of CoVs is the club-shape spike projections emanating from the surface of the virion. These spikes are a defining feature of the virion and give them the appearance of a solar corona, prompting the name CoVs. Within the envelope of the virion is the nucleocapsid. CoVs have helically symmetrical nucleocapsids, which is uncommon among positive-sense RNA viruses but far more common for negative-sense RNA viruses. CoVs virus particles contain four main structural proteins. These are the spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins, all of which are encoded within the 3 0 end of the viral genome. The distinctive spike structure on the surface of CoV is comprised of trimers of S molecules [14, 15] . The S protein is a class I viral fusion protein [16] . It binds to host cell receptors and mediates the earliest infection steps. In some case it also induces cell-cell fusion in late infection. The S monomer is a transmembrane protein with mass ranging from 126 to 168 kDa and is heavily N-linked glycosylated, increasing the apparent molecular weight by some 40 kDa. In most, but not all CoVs S is cleaved by a host cell furin-like protease into two separate polypeptides, S1 and S2 [17] [18] [19] The E protein is a small protein with a size 8-12 kDa and is found in small quantities within the virion [39]. E proteins from different CoVs are highly divergent but share a common architecture: a short hydrophilic N-terminal, followed by a large hydrophobic region, and, lastly, a large hydrophilic C-terminal tail. The membrane topology of E protein is not completely resolved [40] [41] [42] , but most data suggest that it is a transmembrane protein.

The E protein has ion channel activity and was observed to assemble into homooligomers, ranging from dimers through hexamers [43] , and a pentameric α-helical bundle structure has been solved for the hydrophobic region of SARS-CoV E protein [44] . An oligomeric form is consistent with the ion channel activity of the E protein, but the monomeric form of E may also play a separate role. As opposed to other structural proteins, recombinant viruses lacking the E protein are not always lethal, although this is virus type dependent [45, 46] . The E protein facilitates assembly and release of the virus but also has other functions. For instance, SARS-CoV E protein is not required for viral replication but is required for pathogenesis [47, 48] .

The N protein constitutes the only protein present in the helical nucleocapsid. It is composed of two independently folding domains, an N-terminal domain (NTD) and a C-terminal domain (CTD), both capable of binding RNA in vitro, but each domain uses different mechanisms to bind RNA. It has been suggested that optimal RNA binding requires contributions from both domains [49, 50] . N protein is heavily phosphorylated [51], which may be important for triggering a structural change enhancing the affinity for viral versus nonviral RNA, and is ADP ribosylated [52] . N protein binds the viral genome in a beads-on-a-string type conformation. Two specific RNA substrates have been identified for N protein: the transcription-regulating sequences (TRSs) [53] and the genomic packaging signal. The genomic packaging signal has been found to bind specifically to the second, or C-terminal RNA binding domain [38] . N protein also binds to nsp3 [50, 54], a key component of the replicase-transcriptase complex (RTC), and to the M protein [26] . These protein interactions serve to tether the viral genome to the RTC and subsequently package the encapsidated genome into viral particles.

Hemagglutinin-esterase (HE), a fifth structural protein, is present only in a subset of β-CoVs, which include MHV, BCoV, HCoV-OC43, and HCoV-HKU1. The protein acts as a hemagglutinin, binds sialic acids on surface glycoproteins, and contains acetylesterase activity [55] . These activities are thought to enhance S protein-mediated cell entry and virus spread through the mucosa [56] . Interestingly, HE enhances murine hepatitis virus (MHV) neurovirulence [1] ; however, it is selected against in tissue culture for unknown reasons [57].

The initial attachment of the virion to the host cell is initiated by interactions between the S protein and its receptor. This interaction is the primary determinant controlling CoVs host species range and tissue tropism. Individual CoVs usually infects one or a few closely related hosts. S protein includes two subunits, the comparatively variable S1 subunit mediates the binding to receptor and the more conserved S2 subunit undergoes large conformational changes that results in fusion of virion and cell membranes. The sites of receptor binding domains (RBD) within the S1 region of a CoVs S protein vary depending on the virus: the RBD located at the N-terminal of S1 (MHV) in some cases [58] while it is present in the C-terminal of S1 in the case of SARS-CoV SARS-CoV uses angiotensin-converting enzyme 2 (ACE2) as its receptor [78] . ACE2 is mainly expressed in epithelial cells of the lung and the small intestine, the primary targets of SARS-CoV, and also in heart, kidney, and other tissues [79] . ACE2 is a cell-surface, zinc-binding carboxypeptidase and plays a role in regulation of cardiac function and blood pressure. ACE2 also serves as the receptor for the α-CoV HCoV-NL63 [80].

MERS-CoV uses dipeptidyl-peptidase 4 (DPP4) as its cellular receptor [81] . DPP4, also called CD26, is a membrane-bound exoprotease with a wide tissue distribution; it cleaves dipeptides from hormones, chemokines, and cytokines and plays multiple other physiological functions Table 1 for a list of known CoVs receptors).

Many CoVs S proteins are cleaved during exit from the producer cells, often by a furin-like protein [17] . This cleavage separates the RBD and fusion domains of the S protein [83]. Following receptor binding, the virus must next gain access to the host cell cytosol. This is generally accomplished by a second proteolytic cleavage of the S protein by TMPRRS2, a cathepsin or another protease [84, 85] . Following cleavage at S2 0 , a fusion peptide is exposed, which is followed by joining of two heptad repeats in S2 . This may have been driven by the antivirus neutralizing antibody response, but this is not certain. One interpretation is that, in the case of MERS-CoV, receptor binding is less important than other parts of the entry process, such as S protein cleavage by host cell proteases, particularly TMPRSS2 [91].

The next step in the CoVs lifecycle is the translation of the replicase gene from the virion genomic RNA. The replicase gene encodes two large ORFS, rep1a and rep1b, which express two coterminal polyproteins, pp1a and pp1ab (Fig. 1) . In order to express both polyproteins, the virus utilizes a slippery sequence (5 0 -UUUAAAC-3 0 ) and an RNA pseudoknot that cause ribosomal frameshifting from the rep1a reading frame into the rep1b ORF. In most cases, the ribosome unwinds the pseudoknot structure and continues translation until it encounters the rep1a stop codon. Occasionally the pseudoknot blocks the ribosome from continuing elongation, causing it to pause on the slippery sequence, changing the reading frame by moving back one nucleotide (À1 frameshift) before the ribosome is able to melt the pseudoknot structure and extend translation into rep1b, resulting in the translation of pp1ab [92, 93] . In vitro studies predict the incidence of ribosomal frameshifting to be as high as 25%, but this has not been determined in the context of virus infection. Viruses probably utilize frameshifting to control the precise ratio of rep1b:rep1a proteins or delay the production of rep1b products until the products of rep1a have created a suitable environment for RNA replication [94] .

Polyproteins pp1a and pp1ab contain the nsps 1-11 and 1-16 respectively. In pp1ab, nsp11 from pp1a becomes nsp12 following extension of pp1a into pp1b. However, γ-CoVs do not contain a comparable nsp1. These polyproteins are subsequently cleaved into individual nsps [95] . There are two types of polyprotein cleavage activity. One or two papain-like proteases (PLpro), which are situated within nsp3, carry out the relatively specialized separations of nsp1, nsp2, and nsp3. Many PLpro also have deubiquitinase activity, which counters some host antiviral defenses [ [117, 118] . For a list of nonstructural proteins and their putative functions, see Table 2 . Ribonucleases nsp15-NendoU and nsp14-ExoN activities are unique to the Nidovirales order and are considered genetic markers for these viruses [119].

Viral RNA synthesis follows the translation and assembly of the viral replicase complexes. Viral RNA synthesis produces both genomic and subgenomic RNAs. Subgenomic RNAs serve as mRNAs for Perhaps the most novel aspect of CoV replication is how the leader and body TRS segments fuse during production of subgenomic RNAs. Leader-TRS joining occurs during the discontinuous extension of negative-strand RNA [130] . The current model proposes that the RdRp pauses at body TRS sequences (TRS-B); following this pause, the RdRp either continues elongation to the next TRS or switches to amplifying the leader sequence at the 5 0 end of the genome guided by complementarity of the TRS-B to the leader TRS (TRS-L). Furthermore, nucleocapsid phosphorylation and RNA helicase DDX1 recruitment was shown to facilitate the transition from discontinuous to continuous transcription [131] . However, many questions remain. For instance, how does the RdRp bypass all of the TRS-B sequences to produce full-length negative-strand genomic RNA? Also, how are the TRS-B sequences directed to the TRS-L and how much complementarity is necessary? Answers to these questions and others will be necessary to gain a full perspective of how RNA replication occurs in CoVs. Eventual development of an in vitro replication system will be required to fully understand these processes.

Finally, CoVs are also known for their ability to recombine by both homologous and nonhomologous recombination [132, 133] . The ability of these viruses to recombine is tied to the strand switching ability of the RdRp. Recombination likely plays a prominent role in viral evolution and is the basis for targeted RNA recombination [134], a reverse genetics tool used to engineer viral recombinants at the 3 0 end of the genome.

Following replication and subgenomic RNA synthesis, the viral structural proteins, S, E, and M are translated and inserted into the endoplasmic reticulum (ER). These proteins move along the secretory pathway into the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) [135, 136] . There, viral genomes encapsidated by N protein bud into membranes of the ERGIC containing viral structural proteins, forming mature virions [137] .

The M protein directs most protein-protein interactions required for assembly of CoVs. M protein is not sufficient for virion formation as virus-like particles (VLPs) cannot be formed by M protein expression alone. However, when M protein is expressed along with E protein, VLPs are formed, suggesting these two proteins function together to produce CoV envelopes [138] . N protein enhances VLP formation, suggesting that fusion of encapsidated genomes into the ERGIC enhances viral envelopment [139] . The S protein is incorporated into virions at this step but is not required for assembly. The ability of the S protein to traffic to the ERGIC and interact with the M protein is critical for its incorporation into virions.

While the M protein is relatively abundant, the E protein is only present in small quantities in the virion. Thus, it is likely that M protein interactions provide the impetus for envelope maturation. E protein may assist the M protein in virion assembly either by inducing membrane curvature [46, 140, 141], preventing the aggregation of M protein [142], or by an uncharacterized mechanism. The E protein may also have a separate role in promoting viral release by altering the host secretory pathway [143] .

The M protein also binds to the nucleocapsid, and this interaction promotes the completion of virion assembly. These interactions have been mapped to the C-terminus of the endodomain of M with CTD 3 of the N-protein [144] . However, it is unclear exactly how the nucleocapsid complexed with virion RNA traffics from the RTC to the ERGIC to interact with M protein and become incorporated into the viral envelope. Another outstanding question is how the N protein selectively packages only positivesense full-length genomes among the many different RNA species produced during infection. A packaging signal for MHV is present in the nsp15 coding sequence [38] . Mutation of this signal drastically increases sgRNA incorporation into virions, and while virus production in cultured cells is negligibly affected, the mutant virus elicits a stronger IFN response in mice [145] . Furthermore, most CoVs do not contain similar sequences at this locus, indicating that packaging may be virus specific.

Following assembly, virions are transported to the cell surface in vesicles and released by exocytosis. It is not known if the virions use a traditional pathway for transport of large cargo from the Golgi or if the virus has diverted a separate, unique pathway for its own exit. Genome-wide screening has identified a host protein, valosin-containing protein (VCP/p97) that is required for release of CoV from endosomes [146] . In several CoVs, S protein that does not assemble into virions transits to the cell surface where it mediates cell-cell fusion between infected cells and adjacent, uninfected cells. This leads to the formation of multinucleated cells, which allows the virus to spread within an infected organism without being detected or neutralized by virus-specific antibodies.

CoVs cause a large variety of diseases in animals, and their ability to cause severe disease in livestock and companion animals such as pigs, cows, chickens, dogs, and cats led to significant research on these viruses in the last half of the twentieth century. For instance, Transmissible Gastroenteritis Virus (TGEV) and Porcine Epidemic Diarrhea Virus (PEDV) cause severe gastroenteritis in young piglets, leading to significant morbidity, mortality, and ultimately economic losses. Recently a novel HKU2-related bat CoV, Swine Acute diarrhea Syndrome Coronavirus (SADS-CoV), was shown to cause an outbreak of fetal swine disease [147] . Porcine Hemagglutinating Encephalomyelitis Virus (PHEV) causes enteric infection but has the ability to infect the nervous system, causing encephalitis, vomiting and wasting in pigs. Feline enteric coronavirus (FCoV) causes a mild or asymptomatic infection in domestic cats, but during persistent infection, mutation transforms the virus into a highly virulent strain of FCoV (Feline Infectious Peritonitis Virus, FIPV) that leads to development of a lethal disease called feline infectious peritonitis (FIP). FIPV is macrophage tropic and is believed to cause aberrant cytokine and/or chemokine expression and lymphocyte depletion, resulting in lethal disease [148] . Bovine CoV, Rat CoV, and Infectious Bronchitis Virus (IBV) cause mild to severe respiratory tract infections in cattle, rats, and chickens respectively. Bovine CoV causes significant losses in the cattle industry and also has spread to infect a variety of ruminants, including elk, deer, and camels. In addition to severe respiratory disease, the virus causes diarrhea ("winter dysentery" and "shipping fever"), all leading to weight loss, dehydration, and decreased milk production [149] . Some strains of IBV, a γ-CoV, also infect the urogenital tract of chickens causing renal disease. IBV significantly diminishes egg production and weight gain, causing substantial losses in the chicken industry each year [150] . Interestingly, a novel CoV (SW1) was identified in a deceased Beluga whale [151] and shown to be a γ-CoV based on phylogenetic analysis. This is the first example of a nonavian γ-CoV, but it is not known whether this virus actually causes disease in whales.

In addition, there has been intense interest in identifying novel bat CoVs, since these are the likely ultimate source for most CoV, including SARS-CoV and MERS-CoV [152, 153] . Hundreds of novel bat CoV have been identified over the past decade [154], including the agent of SADS, described above. Another novel, non-CoVs group of nidoviruses, Mesoniviridae, were recently identified as the first ones to exclusively infect insect hosts [155, 156] . These viruses are highly divergent from other nidoviruses but are most closely related to the roniviruses. In size, they are~20 kb, falling in between large and small nidoviruses. Consistent with this relatively small size, these viruses do not encode for an endoribonuclease, which is present in large nidoviruses. Recently a novel nidovirus, planarian secretory cell nidovirus (PSCNV), was identified and shown to have a 41.1 kb genome, making it the largest RNA viral genome yet discovered. The genome contains the canonical nidoviral genome organization and key replicative domains. It encodes a predicted 13,556 aa polyprotein in an unconventional single ORF [157] .

The most heavily studied animal CoV is murine hepatitis virus (MHV), which causes multiple diseases in mice, including respiratory, enteric, hepatic, and neurologic infections. For instance, MHV-1 causes severe respiratory disease in susceptible A/J and C3H/HeJ mice, A59 and MHV-3 induce hepatitis, and JHMV causes encephalitis and acute and chronic demyelinating diseases. MHV-3 induces cellular injury through the activation of the coagulation cascade via a fgl2/fibroleukin dependent way [158] . A59 and attenuated versions of JHMV cause chronic demyelinating diseases that bears similarities to multiple sclerosis (MS), making MHV infection one of the best models for this debilitating human disease. Early studies suggested that demyelination was dependent on viral replication in oligodendrocytes in the brain and spinal cord [159, 160]; however, more recent reports clearly demonstrate that the disease is immune-mediated. Irradiated mice or immunodeficient (lacking T and B cells) mice do not develop demyelination, but addition of virus-specific T cells restores the development of demyelination [161] [162] [163] . Additionally, demyelination is accompanied by a large influx of macrophages and microglia that can phagocytose infected myelin [164] . Microglia are especially important in the initial host defense to MHV since mice succumb to the infection if these cells are depleted [165].

Prior to the SARS-CoV outbreak, CoVs were only thought to cause mild, self-limiting respiratory infections in humans. Two of these human CoVs are α-CoVs (HCoV-229E and HCoV-NL63), while the other two are β-CoVs (HCoV-OC43 and HCoV-HKU1). HCoV-229E and HCoV-OC43 were isolated nearly 50 years ago [166-168], while HCoV-NL63 and HCoV-HKU1 were only identified following the SARS-CoV outbreak [169, 170] . HCoV-229E and HCoV-NL63 arose from a common ancestor and diverged 200 years ago [171] . HCoV-OC43 is closely related to BCoV and may have crossed species from bovids, or alternatively, may have been transmitted from humans to cows. These viruses are endemic in the human populations, causing 15-30% of upper respiratory tract infections each year. They cause more severe disease in neonates, the elderly, and in individuals with underlying illnesses, with a greater incidence of lower respiratory tract infection in these populations [172] . HCoV-NL63 is also associated with acute laryngotracheitis (croup) [173] . One interesting aspect of these viruses is their differences in tolerance to genetic variability. HCoV-229E isolates from around the world have only minimal sequence divergence [174], while HCoV-OC43 isolates from the same location but isolated in different years show significant genetic variability [175] . Based on the ability of MHV to cause demyelinating disease, it has been suggested that human CoVs may be Transmission of SARS-CoV was relatively inefficient, as it largely spread through large droplets and direct contact with infected individuals and transmission only occurred after the onset of clinical illness. Thus, the outbreak mostly occurred within households and healthcare settings [182], except in a few cases of superspreading events where one individual was able to infect multiple contacts due to high viral burdens or an ability to aerosolize virus. As a result of the relatively inefficient transmission of SARS-CoV, the outbreak was controllable through the use of quarantining. Only a small number of SARS cases occurred after the outbreak was controlled in June 2003 [183] .

SARS-CoV primarily infects epithelial cells within the lung [184]. The virus is capable of entering macrophages and dendritic cells but only causes an abortive infection [185, 186] . Despite this, infection of these cell types may be important in inducing proinflammatory cytokines that may contribute to disease [187] . In fact, many cytokines and chemokines are produced by these cell types and are elevated in the serum of SARS-CoV infected patients [188] . Viral titers decrease when severe disease develops in both humans and in several animal models of the disease, suggesting that the host response is responsible for much of the clinical signs and symptoms. Furthermore, animals infected with rodent-adapted SARS-CoV strains show similar clinical features to the human disease, including an age-dependent increase in disease severity [189] . These animals also show increased levels of proinflammatory cytokines and reduced T-cell responses, consistent with a possible immunopathological mechanism of disease [190, 191] .

While the SARS-CoV epidemic was controlled in 2003, and the virus has not since returned, a novel human CoV emerged in the Middle East in 2012. This virus, named Middle East Respiratory Syndrome-CoV (MERS-CoV), is a group 2b β-CoV and was found to be the causative agent of a highly lethal respiratory tract infection in Saudi Arabia and other countries in the Middle East [153, 192] . Since its emergence, the virus has spread to over 27 countries, including to South Korea in 2015, where it caused 186 cases and 38 deaths [193] . Among those cases, 83% were transmitted from five super spreading events and 44% were due to nosocomial transmission at 16 hospitals [194] . As of September 2019, there have been a total of 2468 laboratory-confirmed cases of MERS-CoV, with 851 associated deaths and a case fatality rate of approximately 35%, as reported to the World Health Organization (https://www.who.int/emergencies/mers-cov/en/). The majority of cases early in the outbreak resulted from nosocomial transmission. As better infection control measures were instituted, approximately 50% of cases are considered primary, with infection resulting from direct or indirect contact with camels, the zoonotic source of the infection [195] . Serological studies have identified MERS-CoV antibodies in dromedary camels in the Middle East and Africa from samples obtained as early as 1983 [196] . Supporting evidence for camel to human transmission comes from studies identifying nearly identical MERS-CoVs in camels and humans in nearby proximities in Saudi Arabia [5, 23, 197] . In one of these studies the human case had direct contact with an infected camel and the virus isolated from this patient was nearly identical to the virus isolated from the camel [5] . MERS-CoV likely originated in bats because it is related to two previously identified bat CoV, HKU4 and HKU5 [198] . Furthermore, new evidence has emerged to support the hypothesis that bats are the evolutionary source of MERS-CoV since a MERS-like CoV was identified from a Pipistrellus cf. hesperidus bat sampled in Uganda [199] .

MERS-CoV utilizes Dipeptidyl peptidase 4 (DPP4) as its receptor [81]. The virus is only able to use the receptor from certain species such as bats, humans, camels, rabbits, and horses to establish infection. While the virus is unable to naturally infect mouse cells due to differences in the structure of DPP4, several mouse models expressing human DPP4 have been developed which can successfully be infected with MERS-CoV [200] [201] [202] [203] .

In most cases of self-limited infection, diagnosis of CoVs is unnecessary. However, it is important in certain clinical and veterinary settings or in epidemiological studies to identify an etiological agent. Diagnosis is also important in locations where a severe CoV outbreak is occurring, such as, at present, in the Middle East, where MERS-CoV continues to circulate. The identification of cases will guide the development of public health measures to control outbreaks. It is also important to diagnose cases of severe veterinary CoV-induced disease, such as PEDV and IBV, to control these pathogens and protect food supplies. The primary methods to diagnose CoV infection use molecular techniques such as RT-PCR. RT-PCR has become the method of choice for diagnosis of human CoV, as multiplex real-time RT-PCR assays, such as RT-RTPA, and RT-LAMP, have been developed. They are able to detect all four respiratory human CoVs and could be further adapted to detect novel CoVs [204, 205] . Serologic assays are important in cases where RNA is difficult to isolate, virus is no longer present, and for epidemiological studies. Because rapid and accurate diagnosis of MERS is important, several diagnostic tests including one in which RT-LAMP is combined with vertical flow visualization (RT-LAMP-VF) [206] have been developed.

To date, there are no antiviral therapeutics that specifically target human CoVs, so treatments are only supportive. IFNs have been used in some patients, without evidence of therapeutic benefit [207] . Studies in mice indicate that the relative timing of IFN administration and virus replication are critical to either protective or pathogenic effects after infection with SARS-CoV [208] or MERS-CoV [209] , which may explain the variable results that are observed in patients. The SARS and MERS outbreaks have stimulated research on these viruses, and this research has identified a large number of suitable antiviral targets, such as viral proteases, polymerases, and entry proteins, but so far no specific treatment has been licensed. Multitarget treatment should be a priority as for antiviral treatment [210, 211] . Significant work remains to develop drugs that target these processes and are useful in infected patients.

Many CoV-specific vaccines have been developed and some targeting veterinary CoV pathogens have been licensed. Vaccines have been approved for IBV [212] , TGEV [213] , and canine CoV, but these vaccines are not always used because they are either not very effective, or in some cases, have resulted in the selection of novel pathogenic CoVs via recombination of circulating strains [214] . In general, it is thought that live attenuated vaccines are most efficacious in targeting CoVs. This was illustrated in the case of TGEV, where an attenuated naturally appearing variant, porcine respiratory coronavirus (PRCoV), appeared in Europe in the 1980s. This variant only caused mild disease and protected swine from lethal TGEV. This attenuated virus has prevented the recurrence of severe TGEV in Europe and the USA over the past 30 years [215] .

In the case of SARS-CoV, several potential vaccines have been developed. The spike protein, which elicits a neutralizing antibody response, has been a major target of vaccine development [216, 217] . Therapeutic SARS-CoV neutralizing human monoclonal antibodies have been generated and stockpiled [218] . These antibodies would be useful for passive immunization of healthcare workers and other high-risk individuals in the event of another SARS outbreak [219] . Similarly, efforts have been made to develop vaccines against MERS-CoV. Several vaccine approaches have been tried, including subunits vaccines, DNA vaccines, viral vector vaccines and live attenuated and inactivated vaccines [220, 221] . Some of these have shown efficacy in animal testing and several are in clinical trials. For example, a MERS-CoV DNA vaccine recently underwent phase I Clinical Trials [222, 223] ; while it induced MERS-CoV-specific neutralizing antibody titers, these tended to decline substantially by 60 weeks after immunization.

Owing to the lack of effective therapeutics or vaccines, the best measures to contain human CoVs outbreaks remain a strong public health surveillance system coupled with rapid diagnostic testing and quarantine when necessary. For international outbreaks, cooperation of governmental entities, public health authorities, and health care providers is critical. During outbreaks of veterinary CoV that are readily transmitted, such as PEDV, more drastic measures such as culling of entire herds of pigs may be necessary to prevent transmission of these deadly viruses.

Over the last half century, several varieties of CoVs have emerged to cause human and veterinary diseases. It is likely that these viruses will continue to emerge and evolve, and cause both human and veterinary outbreaks owing to their ability to recombine, mutate, and infect various animal species and cell types.

Critical problems remain to be resolved in future research. One focus should be to understand viral replication and pathogenesis in greater detail. Another is to explore the propensity of these viruses to cross species and the features that facilitate or inhibit crossspecies transmission and to identify CoVs reservoirs, which will enhance our ability to predict potential future epidemics. So far, bats seem to be a primary reservoir for these viruses, but they do not develop clinically evident disease, for reasons that require further investigation. Additionally, many of the nonstructural and accessory proteins encoded by CoVs are only partly characterized, and it will be important to identify their mechanisms of action and their role in viral replication and pathogenesis. These studies will help identify more suitable therapeutic targets. Finally, additional studies should probe CoV-induced immunopathological disease and delineate the relationship between CoVs and the host immune response. These will guide efforts to design vaccines and drugs that prevent and treat CoV infections. (2) 

Expression of hemagglutinin esterase protein from recombinant mouse hepatitis virus enhances neurovirulence

The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host

Coronavirus gene 7 counteracts host defenses and modulates virus virulence

Severe acute respiratory syndrome coronavirus protein 6 accelerates murine coronavirus infections

Evidence for camel-tohuman transmission of MERS coronavirus

MERS-CoV accessory ORFs play key role for infection and pathogenesis

MERS outbreak in Korea: hospital-to-hospital transmission

Reported direct and indirect contact with dromedary camels among laboratory-confirmed MERS-CoV cases

Middle East respiratory syndrome coronavirus (MERS-CoV) origin and animal reservoir

Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia

Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans

Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus

Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice

Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease

Rapid generation of a mouse model for Middle East respiratory syndrome

A mouse model for MERS coronavirus-induced acute respiratory distress syndrome

Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus

Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method

A rapid and specific assay for the detection of MERS-CoV

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study

Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice

IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes

Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape

A review of treatment modalities for Middle East respiratory syndrome

Vaccination against infectious bronchitis virus: a continuous challenge

An overview of successful TGEV vaccination strategies and discussion on the interrelationship between TGEV and PRCV

Global trends in emerging infectious diseases

Porcine respiratory coronavirus: molecular features and virus-host interactions

Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine

Development of a SARS coronavirus vaccine from recombinant spike protein Plus Delta inulin adjuvant

Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine

Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential

Middle East respiratory syndrome vaccine candidates: cautious optimism

Vaccine against Middle East respiratory syndrome coronavirus

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

First clinical trial of a MERS coronavirus DNA vaccine

Type I feline coronavirus spike glycoprotein fails to recognize aminopeptidase N as a functional receptor on feline cell lines

Porcine aminopeptidase N is not a cellular receptor of porcine epidemic diarrhea virus, but promotes its infectivity via aminopeptidase activity

Aminopeptidase N is not required for porcine epidemic diarrhea virus cell entry

Bovine coronavirus uses N-acetyl-9-O-acetylneuraminic acid as a receptor determinant to initiate the infection of cultured cells

Structural and functional analysis of the surface protein of human coronavirus OC43

Mapping of the receptor-binding domain and amino acids critical for attachment in the spike protein of avian coronavirus infectious bronchitis virus

Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines

The endonucleolytic RNA cleavage function of nsp1 of Middle East respiratory syndrome coronavirus promotes the production of infectious virus particles in specific human cell lines

The nsp2 replicase proteins of murine hepatitis virus and severe acute respiratory syndrome coronavirus are dispensable for viral replication

Severe acute respiratory syndrome coronavirus nonstructural protein 2 interacts with a host protein complex involved in mitochondrial biogenesis and intracellular signaling

Nuclear magnetic resonance structure shows that the severe acute respiratory syndrome coronavirusunique domain contains a macrodomain fold

Structural and functional basis for ADP-ribose and poly (ADP-ribose) binding by viral macro domains

Mouse hepatitis virus liver pathology is dependent on ADP-ribose-1 00 -phosphatase, a viral function conserved in the alpha-like supergroup

Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling

Nuclear magnetic resonance structure of the N-terminal domain of nonstructural protein 3 from the severe acute respiratory syndrome coronavirus

Nuclear magnetic resonance structure of the nucleic acid-binding domain of severe acute respiratory syndrome coronavirus nonstructural protein 3

The autocatalytic release of a putative RNA virus transcription factor from its polyprotein precursor involves two paralogous papain-like proteases that cleave the same peptide bond

Mutation in murine coronavirus replication protein nsp4 alters assembly of double membrane vesicles

Murine hepatitis virus nonstructural protein 4 regulates virusinduced membrane modifications and replication complex function

Identification and characterization of a serine-like proteinase of the murine coronavirus MHV-A59

Porcine deltacoronavirus nsp5 inhibits interferon-beta production through the cleavage of NEMO

Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world

Dimerization of coronavirus nsp9 with diverse modes enhances its nucleic acid binding affinity

In vitro reconstitution of SARS-coronavirus mRNA cap methylation

Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2'-O-methyltransferase nsp10/ nsp16 complex

Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design

Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase

Human coronavirus 229E nonstructural protein 13: characterization of duplex-unwinding, nucleoside triphosphatase, and RNA 5 0 -triphosphatase activities

Mutagenesis of coronavirus nsp14 reveals its potential role in modulation of the innate immune response

Murine hepatitis virus nsp14 exoribonuclease activity is required for resistance to innate immunity

RNA recognition and cleavage by the SARS coronavirus endoribonuclease

Major genetic marker of nidoviruses encodes a replicative endoribonuclease

In situ tagged nsp15 reveals interactions with coronavirus replication/transcription complex-associated proteins

Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5